Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
Hodgkin's disease and HIV infection (HD-HIV): a report of 92 patients from the GICAT (Italian Cooperative Group on AIDS and Tumors), with emphasis on prospective study with combined chemotherapy and zidovudine (AZT) in 16 patients.
Int Conf AIDS. 1992 Jul 19-24;8(1):Mo16 (abstract no. MoB 0059). Unique Identifier : AIDSLINE ICA8/92400016 Vaccher E; Tirelli U; Milo D; Chieppa F; Alberici F; Branz F; Ambrosini G; Giudici M; Lazzarin A; Cargnel A; et al; Centro di Riferimento Oncologico Aviano, Italy.
Abstract:
Between November 1986 and June 1991, 92 pts (84 M, 8 F) with HD-HIV were seen by the GICAT. 83% were IVDU, 8% homosexual men, 5% IVDU+homosexual and 4% heterosexuals. At diagnosis of HD-HIV, 16% pts had AIDS, 20% ARC, 33% PGL and 31% were asymptomatic; median CD4 count was 249/mmc. LP subtype was diagnosed in 2%, NS in 21%, MC in 48% and LD in 22% of pts: 27% and 53% were stage III and IV respectively. 44 pts were treated with MOPP or MOPP+ABVD +/- RT (AZT was not given) with CR in 50% and PR in 45% of pts. Median survival was 16 months. 61% of pts developed OI during therapy or follow-up. MOPP+ABVD seemed better tolerated than MOPP alone. Between March 1989 and March 1991, 16 consecutive previously untreated pts were enrolled in a prospective study with combined CT and AZT. Pts were stratified in two groups. Group A: pts with PS less than 3 and without OI received Epirubicin 70 mg/m2 i.v. dl, Bleomycin 10 mg/m2 i.v. dl and Vinblastine 6 mg/m2 i.v. dl (EBV): Group B: pts with PS greater than or equal to 3 and/or OI received a 50% reduced dose of E and V and full dose of B. Courses were repeated every 21 days for 6 cycles. AZT was given at the dose of 500 mg/day per os from the beginning of CT in group B and after the third cycle in group A. Clinical characteristics were comparable to that of the overall group; median CD4 count was 166/mmc. The median number of cycles administered was 6 (3-6). We observed 7/16 (44%) CR (6/11 in the group A), and 6/16 (38%) PR (4/11 in the group A). A CD4+ cell count greater than 150/mmc was not significantly related to the achievement of CR. 1/13 pt developed OI during CT or follow-up. The median CD4 count after therapy was 203/mmc, while none of 9 pts with a negative Ag p24 prior to therapy became positive. Toxicity was moderate. The median survival was 10.5 months. Objective response rate seems similar to that previously observed within the GICAT for pts receiving standard CT, but only one OI occurred and this compares favourably with that observed in pts treated with standard CT without AZT.
Keywords: Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Dacarbazine/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Epirubicin/ADMINISTRATION & DOSAGE Hodgkin's Disease/*COMPLICATIONS/DRUG THERAPY/EPIDEMIOLOGY Homosexuality Human HIV Infections/*COMPLICATIONS/DRUG THERAPY Italy/EPIDEMIOLOGY Male Mechlorethamine/ADMINISTRATION & DOSAGE Prednisone/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE Prospective Studies Sex Behavior Substance Abuse, Intravenous/COMPLICATIONS Survival Analysis Vinblastine/ADMINISTRATION & DOSAGE Vincristine/ADMINISTRATION & DOSAGE Zidovudine/*THERAPEUTIC USE ABSTRACT 921230
M92C5331
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
